Theravance Biopharma Reports Results of Ampreloxetine in P-III (Study 0170) Study for Symptomatic Neurogenic Orthostatic Hypotension
Shots:
- The 2nd P-III (Study 0170) evaluates ampreloxetine vs PBO in patients with symptomatic nOH. The 1EPs were treatment failure @6wks. & showed no significant results for the overall population including patients with PD, PAF & MSA, 40% reduction in odds of treatment failure, was well-tolerated with no new safety signals
- In prespecified subgroup analysis, the results showed a benefit in patients with MSA, 72% reduction in odds of treatment failure
- Patients withdrawn to PBP had a relevant decrease in standing blood pressure, no worsening of supine hypertension, following 24hr. monitoring. The company plans to discuss with strategic partners & health authorities to advance ampreloxetine for symptomatic nOH
Ref: Theravance | Image: Theravance
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
